Best Practices Forum: The role of icosapent ethyl for CV risk reduction
Details & Video
Program details and agenda: Select TABS on the left (computer) or SCROLL DOWN (phone)
Perspectives from family practice, diabetology, and cardiology
Overview & Objectives
Perspectives from primary care, diabetology and cardiology.
- To review the role of serum triglycerides as a risk marker vs. a risk factor
- To differentiate icosapent ethyl from standard fish oils
- To best apply the findings from the REDUCE-IT study to clinical practice
This program is NOT accredited.
Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.
Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio.
|Are serum triglycerides a risk factor?|
|Do fish oils reduce CV risk?|
|How does icosapent ethyl differ from fish oils?|
|What are the main results of the REDUCE-IT study?|
|What is the mechanism of benefit?|
|How should we use icosapent ethyl in our practices?|
This program was developed by the Canadian Collaborative Research Network and made possible through an educational grant from HLS Therapeutics Canada.